These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 33130441)

  • 1. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposed modification of the eighth edition of the AJCC-ypTNM staging system of esophageal squamous cell cancer treated with neoadjuvant chemotherapy: Unification of the AJCC staging system and the Japanese classification.
    Oshikiri T; Goto H; Kato T; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Fujino Y; Tominaga M; Kakeji Y
    Eur J Surg Oncol; 2022 Aug; 48(8):1760-1767. PubMed ID: 35094909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of ypTNM Stage Grouping in the 8th Edition of the American Joint Committee on Cancer TNM Staging System for Esophageal Squamous Cell Carcinoma.
    Sudo N; Ichikawa H; Muneoka Y; Hanyu T; Kano Y; Ishikawa T; Hirose Y; Miura K; Shimada Y; Nagahashi M; Sakata J; Kobayashi T; Bamba T; Nakagawa S; Kosugi SI; Wakai T
    Ann Surg Oncol; 2021 Feb; 28(2):650-660. PubMed ID: 33025354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
    Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tumor staging system incorporating cN status for stratifying early stage esophageal squamous cell carcinoma patients after trimodal therapy.
    Li X; Luan S; Zhang C; Kong W; Xiao X; Zhang H; Zhou J; Yang Y; Xu Y; Qiang Y; Fang P; Shen Y; Yuan Y
    Eur J Surg Oncol; 2024 Jan; 50(1):107264. PubMed ID: 37977046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.
    Rice TW; Ishwaran H; Kelsen DP; Hofstetter WL; Apperson-Hansen C; Blackstone EH;
    Dis Esophagus; 2016 Nov; 29(8):906-912. PubMed ID: 27905170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Tumor Staging System Incorporating Tumor Regression Grade (TRG) With Lymph Node Status (ypN-Category) Results in Better Prognostication Than ypTNM Stage Groups After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
    Wong IYH; Chung JCY; Zhang RQ; Gao X; Lam KO; Kwong DLW; Chao YK; Law SYK
    Ann Surg; 2022 Nov; 276(5):784-791. PubMed ID: 35876374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemoradiation Versus Upfront Esophagectomy in Clinical Stage II and III Esophageal Squamous Cell Carcinoma.
    Hsu PK; Chen HS; Liu CC; Wu SC
    Ann Surg Oncol; 2019 Feb; 26(2):506-513. PubMed ID: 30430325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?
    Zou B; Tu Y; Liao D; Xu Y; Wang J; Huang M; Ren L; Zhu J; Gong Y; Liu Y; Zhou L; Zhou X; Peng F; Lu Y
    Thorac Cancer; 2020 Mar; 11(3):631-639. PubMed ID: 31943824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
    Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
    J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the prognostic value of the 6th and 7th editions of the Union for International Cancer Control TNM staging system in patients with lower esophageal cancer undergoing neoadjuvant chemotherapy followed by surgery.
    Mehta SP; Jose P; Mirza A; Pritchard SA; Hayden JD; Grabsch HI
    Dis Esophagus; 2013; 26(2):182-8. PubMed ID: 22591020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
    Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
    JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Yu YK; Meng FY; Wei XF; Chen XK; Li HM; Liu Q; Li CJ; Xie HN; Xu L; Zhang RX; Xing W; Li Y
    J Thorac Cardiovasc Surg; 2024 Aug; 168(2):417-428.e3. PubMed ID: 38246339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the 7th and proposed 8th editions of the AJCC/UICC TNM staging system for esophageal squamous cell carcinoma underwent radical surgery.
    Zhang D; Zheng Y; Wang Z; Huang Q; Cao X; Wang F; Liu S
    Eur J Surg Oncol; 2017 Oct; 43(10):1949-1955. PubMed ID: 28716377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery.
    Lin XW; Chen H; Xie XY; Liu CT; Lin YW; Xu YW; Wang XJ; Wu FC
    Updates Surg; 2024 Aug; 76(4):1377-1388. PubMed ID: 37957531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Kim JY; Yun JK; Kim YH; Park SI; Lee JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Kim SB; Cho KJ; Ryu JS; Kim JH; Kang J; Park SR; Kim HR
    Ann Surg Oncol; 2024 Oct; 31(10):6662-6672. PubMed ID: 38954089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic differences in 8th edition TNM staging of esophagogastric adenocarcinoma after neoadjuvant treatment.
    Sisic L; Blank S; Nienhüser H; Dorr S; Haag GM; Jäger D; Bruckner T; Müller-Stich BP; Ott K; Büchler MW; Ulrich A; Schmidt T
    Eur J Surg Oncol; 2018 Oct; 44(10):1646-1656. PubMed ID: 30082176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.